Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) Director Muneer A. Satter bought 60,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was purchased at an average price of $2.09 per share, with a total value of $125,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of ARPO stock remained flat at $$2.10 during trading hours on Thursday. The stock had a trading volume of 69,125 shares, compared to its average volume of 50,099. Aerpio Pharmaceuticals Inc has a 12 month low of $1.75 and a 12 month high of $5.50.
Aerpio Pharmaceuticals (OTCMKTS:ARPO) last announced its earnings results on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.06). The firm had revenue of $18.82 million during the quarter, compared to the consensus estimate of $18.67 million.
Several hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. grew its holdings in shares of Aerpio Pharmaceuticals by 2.6% during the third quarter. Sphera Funds Management LTD. now owns 1,131,819 shares of the company’s stock worth $3,497,000 after purchasing an additional 28,265 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth $934,000. Nexthera Capital LP bought a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth $1,240,000. FMR LLC bought a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth $3,648,000. Finally, Vanguard Group Inc. bought a new stake in shares of Aerpio Pharmaceuticals during the third quarter worth $3,331,000. Institutional investors own 0.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Muneer A. Satter Purchases 60,000 Shares of Aerpio Pharmaceuticals Inc (ARPO) Stock” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://dakotafinancialnews.com/2018/12/07/muneer-a-satter-purchases-60000-shares-of-aerpio-pharmaceuticals-inc-arpo-stock.html.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Featured Article: What is the quiet period?
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.